MabVax Raises $9.4M In PIPE

San Diego-based oncology drug developer MabVax Therapeutics says it has raised $9.4M in a funding, in a combination of a public offering of its common stock and Series F preferred stock and warrants. The publicly traded company, listed on the Nasdaq as MBVX, said the funding came from OPKO Health. MabVax said the Series F preferred stock went for $4.81 per share of common stock, and included a warrant at $5.55 per share and $6.29 per share. More information »